The data indicate that abrogating the function of endogenous Mer can improve the therapeutic efficacy of elrotinib treatment in otherwise erlotinib-insensitive NSCLC cells harboring EGFR mutation. This evidence concerns the gene MERTK and non-small cell lung carcinoma.